Lilly Cuts Insulin Prices, Reata’s Dramatic FDA Approval, & Seagen M&A Rumors

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Pfizer Acquires Seagen, Sanofi & Novo Cut Insulin Prices, & Illumina’s Proxy Fight
SVB’s Dark Day, Biogen’s Leadership Change, and a Plan to Crush HepC
GSK, Lilly Win FDA Approvals, Magenta For Sale, and a Colossal Series B
VIR’s Scangos Retires, Pliant’s IPF Win, & Some Painful Decisions